Citius Oncology (CTOR) Price & Analysis

Compare

129 Followers

CTOR Stock Chart & Stats

$1.27

-$0.06(-4.78%)

At close: Jan 08 4:00 PM EST

$1.27

-$0.06(-4.78%)

Day’s Range― - ―

52-Week Range$0.55 - $6.19

Previous CloseN/A

Volume120.49K

Average Volume (3M)234.01K

Market Cap

$107.69M

Enterprise Value$315.05M

Total Cash (Recent Filing)$112.00

Total Debt (Recent Filing)$3.80M

Price to Earnings (P/E)―

Beta0.60

Next Earnings

Feb 13, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding84,797,844

10 Day Avg. Volume272,668

30 Day Avg. Volume234,012

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)2.16

Price to Sales (P/S)0.00

P/FCF Ratio-20.41

Enterprise Value/Market Cap2.93

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-12.36

Forecast

1Y Price Target

$6.00

Price Target Upside372.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

CommercializationFinalizing the commercial agreement is a key step towards ensuring a successful launch that can unlock the value in Lymphir.

Manufacturing And DistributionCitius has completed commercial-scale manufacturing and has entered into distribution partnerships with leading companies such as Cardinal Health.

Market AccessLymphir has gained a permanent J-code to enable market access.

Bears Say

Citius Oncology News

Citius Oncology reports FY25 EPS (34c) vs. (31c) last year

“2025 was a landmark year for Citius Oncology. With the U.S. commercial launch of LYMPHIR now underway, we...

2d ago

CTOR

Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced that it has entered into a definitive...

16d ago

CTOR

CTXR

Citius Oncology expands Lymphir distribution to Turkey and Middle East

Citius Oncology (CTOR)has entered into an exclusive distribution agreement with Er-Kim, a pharmaceutical distributor based in Turkey, for...

21d ago

CTOR

Citius Oncology announces U.S. commercial launch of LYMPHIR

Citius Oncology (CTOR)announced the commercial launch of LYMPHIR. LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by...

24d ago

CTOR

Citius Oncology Raises $18M Through Direct Offering

Citius Oncology ( ($CTOR) ) has provided an announcement. On December 8, 2025, Citius Oncology entered into a...

15d ago

CTOR

Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma

An announcement from Citius Oncology ( ($CTOR) ) is now available. On December 1, 2025, Citius Oncology announced...

24d ago

CTOR

Citius Oncology to advance launch of Lymphir with Verix AI integration

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced a deeper collaboration with Verix, a company...

1M ago

CTOR

CTXR

Citius Oncology Stockholders Approve Share Increase

Citius Oncology ( ($CTOR) ) just unveiled an update. On October 27, 2025, Citius Oncology, Inc. held its...

2M ago

CTOR

Citius Oncology Prepares LYMPHIR Launch for Q4 2025

Citius Oncology ( ($CTOR) ) has shared an announcement. On October 23, 2025, Citius Oncology announced its readiness...

2M ago

CTOR

Citius Oncology announces distribution agreement with McKesson

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced it has entered into a distribution services...

2M ago

MCK

CTOR

Strategic Positioning and Market Potential Drive Buy Rating for Citius Oncology’s Lymphir

Citius Oncology, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from...

2M ago

CTOR

Citius Oncology signs exclusive commercialization agreement with EVERSANA

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced it has finalized an exclusive agreement with...

2M ago

CTOR

CTXR

Citius Oncology’s Strategic Expansion and Market Positioning Drive Buy Rating

Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on Citius Oncology and keeping the price target...

3M ago

CTOR

Citius Oncology signs distribution agreement for Lymphir in Southern Europe

Citius Oncology (CTOR)is engaging with regional distribution partners to make Lymphir available to eligible patients through country-specific Named...

3M ago

CTOR

CTOR FAQ

What was Citius Oncology’s price range in the past 12 months?

Citius Oncology lowest stock price was $0.55 and its highest was $6.19 in the past 12 months.

What is Citius Oncology’s market cap?

Citius Oncology’s market cap is $107.69M.

When is Citius Oncology’s upcoming earnings report date?

Citius Oncology’s upcoming earnings report date is Feb 13, 2026 which is in 50 days.

How were Citius Oncology’s earnings last quarter?

Citius Oncology released its earnings results on Dec 23, 2025. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.

Is Citius Oncology overvalued?

According to Wall Street analysts Citius Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Citius Oncology pay dividends?

Citius Oncology does not currently pay dividends.

What is Citius Oncology’s EPS estimate?

Citius Oncology’s EPS estimate is -0.04.

How many shares outstanding does Citius Oncology have?

Citius Oncology has 84,797,844 shares outstanding.

What happened to Citius Oncology’s price movement after its last earnings report?

Citius Oncology reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Citius Oncology?

Currently, no hedge funds are holding shares in CTOR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Citius Oncology Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

85.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Citius Oncology

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Citius Oncology (CTOR) Earnings & Revenues

Historic Earnings Reports

CTOR Stock 12 Month Forecast

Average Price Target

$6.00

▲(372.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","-1":"-$1","2.25":"$2.25","5.5":"$5.5","8.75":"$8.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.25,5.5,8.75,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,2.28,2.59,2.9,3.21,3.52,3.83,4.14,4.45,4.76,5.07,5.38,5.6899999999999995,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,2.28,2.59,2.9,3.21,3.52,3.83,4.14,4.45,4.76,5.07,5.38,5.6899999999999995,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,2.28,2.59,2.9,3.21,3.52,3.83,4.14,4.45,4.76,5.07,5.38,5.6899999999999995,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.35,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.39,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.77,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.35,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.14,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.89,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >